P1-288: Effects of multimodal cognitive enhancement therapy (MCET) for people with mild cognitive impairment and early stage dementia: A randomized, controlled, double-blind, cross-over trial

2015 ◽  
Vol 11 (7S_Part_10) ◽  
pp. P465-P465 ◽  
Author(s):  
Ki Woong Kim ◽  
Ji Won Han ◽  
Jong Chul Yoon ◽  
Seung-Ho Ryu ◽  
Nam-Jin Lee ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Enhancement ◽  
Early Stage ◽  
Double Blind ◽  
Randomized Controlled

Potenziamento della capacitÀ mentale? Dalla medicalizzazione della cognizione alla farmacologizzazione delle routine mental life

2012 ◽  
pp. 145-159
Author(s):  
Catherine Coveney ◽  
Jonathan Gabe ◽  
Simon Williams
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Research Agenda ◽  
Cognitive Enhancement ◽  
Early Stage ◽  
Mental Life ◽  
Medical Authority ◽  
Pharmaceutical Cognitive Enhancement ◽  
Promise Problems ◽  
Over Time

Sociological engagement with debates around the promise, problems and prospects of pharmaceutical cognitive enhancment is still at an early stage. In this paper we attempt to explore how the prospect of cognitive enhancement can be understood using existing sociological concepts of medicalisation, biomedicalisation and pharmaceuticalisation. Drawing on two case studies, that of Mild Cognitive Impairment (MCI) and the use of modafinil to enhance alertness, we discuss the idea of enhancement medicine and the use of cognitive enhancers outside of medical authority. We suggest that whilst all three of the above concepts shed important light on these developments, overlapping and converging as they do in various ways, pharmaceuticalisation provides a more precise sociological term of reference. We end with some suggestions for a research agenda for tracing and tracking trends in pharmaceutical cognitive enhancement over time.

Boosting brainpower? From the medicalisation of cognition to the pharmaceuticalisation of routine mental life

2013 ◽  
pp. 151-165
Author(s):  
Catherine Coveney ◽  
Jonathan Gabe ◽  
Simon Williams
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Research Agenda ◽  
Cognitive Enhancement ◽  
Early Stage ◽  
Mental Life ◽  
Medical Authority ◽  
Pharmaceutical Cognitive Enhancement ◽  
Promise Problems ◽  
Over Time

Sociological engagement with debates around the promise, problems and prospects of pharmaceutical cognitive enhancment is still at an early stage. In this paper we attempt to explore how the prospect of cognitive enhancement can be understood using existing sociological concepts of medicalisation, biomedicalisation and pharmaceuticalisation. Drawing on two case studies, that of Mild Cognitive Impairment (MCI) and the use of modafinil to enhance alertness, we discuss the idea of enhancement medicine and the use of cognitive enhancers outside of medical authority. We suggest that whilst all three of the above concepts shed important light on these developments, overlapping and converging as they do in various ways, pharmaceuticalisation provides a more precise sociological term of reference. We end with some suggestions for a research agenda for tracing and tracking trends in pharmaceutical cognitive enhancement over time.

Sign in / Sign up

Export Citation Format

Share Document